Xueqian Gong
Associate Vice President, Translational Sciences Eli Lilly & Co.
Seminars
Monday 12th October 2026
Exploring Sofetabart Mipitecan Enhanced Anti-Tumor Activity in Combination with SoC Therapies in Ovarian Cancer Models to Support Clinical Development
10:00 am
- Combining Sofe-M with SoC agents across in vitro and in vivo ovarian cancer models to show superior, well tolerated anti-tumor activity, including enhanced cytotoxicity with olaparib in HRD models
- Sofe-M alone or with bevacizumab was highly effective in induction and subsequent treatment in tumor models with moderate SoC responses
- Contextualizing preclinical findings to support clinical development of Sofe-M in combination with other approved therapeutic agents for ovarian cancer
